Influence of Octreotide and Tamoxifen on Tumor Growth and Liver Metastasis in N-Nitrosobis(2-oxopropyl)amine-Induced Pancreatic Cancer in Syrian Hamsters

In prospective clinical trials single octreotide therapy or combined therapy with tamoxifen has improved the quality of life and survival time in patients with pancreatic cancer. In this study we analyzed the influence of octreotide and tamoxifen on tumor growth and liver metastases in chemically induced pancreatic adenocarcinoma in Syrian hamsters. Octreotide alone and the combined therapy (octreotide/tamoxifen) decreased the incidence of macroscopic pancreatic carcinomas as well as the number and size of liver metastases. The combined therapy showed no superior effect to octreotide alone. Furthermore, there was no difference between the tamoxifen and the control group.

[1]  A. Schally,et al.  Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[2]  P. Malfertheiner,et al.  Treatment of advanced pancreatic cancer with high-dose octreotide , 1993, International journal of pancreatology : official journal of the International Association of Pancreatology.

[3]  A. Griesmacher,et al.  Effects of reactive oxygen species on eicosanoid metabolism in human endothelial cells. , 1992, Prostaglandins.

[4]  J. Laissue,et al.  Multiple actions of somatostatin in neoplastic disease. , 1995, Trends in pharmacological sciences.

[5]  D. Longnecker,et al.  Effects of sex steroid hormones on pancreatic cancer in the rat , 1990, International journal of pancreatology : official journal of the International Association of Pancreatology.

[6]  R. S. Kent,et al.  Regulation of vascular prostaglandin synthesis by metabolites of arachidonic acid in perfused rabbit aorta. , 1983, The Journal of clinical investigation.

[7]  M. L’Abbé,et al.  Dietary (n-3) fatty acids affect rat heart, liver and aorta protective enzyme activities and lipid peroxidation. , 1991, The Journal of nutrition.

[8]  Hallin Pa,et al.  MODELS OF PANCREATIC CANCER , 1993 .

[9]  H. Friess,et al.  Low‐Dose Octreotide Treatment Is Not Effective in Patients with Advanced Pancreatic Cancer , 1993, Pancreas.

[10]  Lamberts Sw,et al.  Etoposide plus carboplatin or cisplatin in good-risk patients with germ cell tumors: a randomized comparison. , 1994 .

[11]  E. Krenning,et al.  The role of somatostatin analogs in the control of tumor growth. , 1994, Seminars in Oncology.

[12]  A. Barkun,et al.  Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas , 1995, Cancer.

[13]  H. Friess,et al.  Role of octreotide in the treatment of pancreatic cancer. , 1994, Digestion.

[14]  R. Woutersen,et al.  Histogenesis of early preneoplastic lesions induced byN-nitrosobis(2-oxopropyl)amine in exocrine pancreas of hamsters , 1989, International journal of pancreatology : official journal of the International Association of Pancreatology.

[15]  P. Hall,et al.  Models of pancreatic cancer. , 1993, Cancer surveys.

[16]  D F Horrobin,et al.  Essential fatty acids: molecular and cellular basis of their anti-cancer action and clinical implications. , 1998, Critical reviews in oncology/hematology.

[17]  A. Schally,et al.  Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters. , 1991, Cancer research.

[18]  F. Boccardo,et al.  Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study , 1992, Cancer.

[19]  J. Klijn,et al.  Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. , 1988, Gastroenterology.

[20]  A. Andrén-sandberg,et al.  Sex hormones and pancreatic cancer. , 1990, Bailliere's clinical gastroenterology.

[21]  A. Schally,et al.  Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[22]  O. M. Taylor,et al.  Classical oestrogen receptor is not detectable in pancreatic adenocarcinoma. , 1992, British Journal of Cancer.

[23]  A. Schally,et al.  Effect of combination treatment with analogs of luteinizing hormone‐releasing hormone (LH‐RH) or somatostatin and 5‐fluorouracil on pancreatic cancer in hamsters , 1991, International journal of cancer.

[24]  D. Jaeck,et al.  Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). The French Associations for Surgical Research. , 1992, American journal of surgery.

[25]  A. Schally,et al.  Mechanisms of Antineoplastic Action of Somatostatin Analogs , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.